Valuation Metrics: From Attractive to Fair
As of 13 April 2026, Apollo Hospitals’ price-to-earnings (P/E) ratio stands at a lofty 59.58, reflecting a premium valuation relative to historical averages and sector norms. This elevated P/E has contributed to the company’s valuation grade being downgraded from “attractive” to “fair” on 9 January 2026. The price-to-book value (P/BV) ratio also remains high at 11.90, underscoring investor willingness to pay a significant premium over the company’s net asset value.
Other valuation multiples reinforce this trend. The enterprise value to EBITDA (EV/EBITDA) ratio is 32.05, while the EV to EBIT ratio is even higher at 42.42. These multiples suggest that Apollo Hospitals is trading at a premium compared to many large-cap peers, reflecting expectations of sustained earnings growth and operational efficiency.
Peer Comparison: Valuation in Context
When compared with Max Healthcare, a key competitor in the hospital sector, Apollo Hospitals appears relatively more reasonably valued. Max Healthcare’s P/E ratio is higher at 63.86, and its EV/EBITDA multiple stands at 44.67, categorising it as “very expensive” by MarketsMOJO’s valuation framework. The PEG ratio, which adjusts the P/E for earnings growth, is 1.54 for Apollo Hospitals versus 1.74 for Max Healthcare, indicating that Apollo’s valuation is more justified by its growth prospects.
These comparisons highlight that while Apollo Hospitals’ valuation has become less attractive, it remains more reasonable than some peers, particularly those with less diversified operations or weaker financial metrics.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Financial Performance and Quality Metrics
Apollo Hospitals’ return on capital employed (ROCE) is a healthy 17.91%, while return on equity (ROE) stands at 18.39%. These figures demonstrate efficient capital utilisation and strong profitability, supporting the premium valuation multiples. However, the dividend yield remains modest at 0.27%, indicating that the company prioritises reinvestment over shareholder payouts, a typical trait for growth-oriented large caps.
The enterprise value to capital employed ratio of 8.11 and EV to sales of 4.67 further illustrate the market’s confidence in Apollo’s ability to generate returns from its asset base and revenue streams. The PEG ratio of 1.54 suggests that the current price reflects expected earnings growth, though it is edging towards the higher side of fair valuation.
Stock Price and Market Performance
At ₹7,527 per share, Apollo Hospitals is trading close to its 52-week high of ₹8,099, with a recent day change of +0.62%. The stock’s volatility remains contained, with intraday prices ranging between ₹7,466 and ₹7,563 on 13 April 2026.
Over various time frames, Apollo Hospitals has outperformed the Sensex significantly. Year-to-date, the stock has gained 6.88%, while the Sensex has declined by 9.00%. Over one year, Apollo’s return is 10.04% compared to the Sensex’s 5.01%. The long-term performance is even more impressive, with a three-year return of 77.66% versus 29.58% for the benchmark, and a five-year return of 140.23% compared to 56.38% for the Sensex. Over a decade, Apollo Hospitals has delivered a staggering 451.11% return, dwarfing the Sensex’s 214.30% gain.
Implications for Investors
The shift from an attractive to a fair valuation grade signals that Apollo Hospitals’ stock price now reflects much of the company’s growth potential and operational strengths. While the premium multiples are justified by strong returns and quality metrics, the elevated P/E and P/BV ratios suggest limited upside from current levels without further earnings acceleration.
Investors should weigh the company’s robust fundamentals and market leadership against the stretched valuation. The modest dividend yield and high reinvestment rate imply that capital gains remain the primary return driver. Given the hospital sector’s growth prospects amid rising healthcare demand, Apollo Hospitals remains a core holding for those favouring quality large caps, but with a cautious stance on valuation risk.
Is Apollo Hospitals Enterprise Ltd. your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Conclusion: Valuation Caution Amid Strong Fundamentals
Apollo Hospitals Enterprise Ltd. continues to be a dominant player in India’s hospital sector, delivering superior returns and maintaining strong profitability metrics. However, the recent downgrade in valuation grade from attractive to fair reflects a market pricing in much of the company’s growth story. Investors should approach the stock with measured expectations, recognising that while the fundamentals remain sound, the premium multiples limit near-term upside.
For those seeking exposure to the hospital sector, Apollo Hospitals offers quality and stability, but it is prudent to monitor valuation trends closely and consider peer comparisons to optimise portfolio allocation.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
